Selgantolimod

DRUG5 trials

Sponsors

ANRS Maladies Infectieuses Emergentes, Gilead Sciences, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Chronic Hepatitis BHBVHIV InfectionsHepatitis B

Phase 2

Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B

CompletedNCT03491553

Gilead SciencesChronic Hepatitis B

Start: 2018-04-06End: 2020-08-10Updated: 2021-08-19

Study to Evaluate the Safety, Tolerability, and Antiviral Activity of Selgantolimod (Formerly GS-9688) in Viremic Adult Participants With Chronic Hepatitis B (CHB) Who Are Not Currently on Treatment

CompletedNCT03615066

Gilead SciencesChronic Hepatitis B

Start: 2018-08-28End: 2021-04-12Updated: 2022-05-10

Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)

CompletedNCT04891770

Gilead SciencesChronic Hepatitis B

Start: 2021-08-14End: 2024-07-19Updated: 2025-07-24

Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV

Active, not recruitingNCT05551273

National Institute of Allergy and Infectious Diseases (NIAID)Hepatitis B, HIV Infections

Start: 2023-05-05End: 2026-04-29Updated: 2026-03-19

ANRS HB07 IP-Cure-B proof of concept (PoC) clinical trial. Educating the liver immune environment through TLR8 stimulation followed by NUC discontinuation.

Active, not recruitingCTIS2024-515739-32-00

ANRS Maladies Infectieuses EmergentesHBV

Start: 2022-01-10Target: 51Updated: 2025-12-31

Related Papers

Safety, pharmacodynamics, and antiviral activity of selgantolimod in viremic patients with chronic hepatitis B virus infection.

2023-11-309 citations

Design and analysis considerations for early phase clinical trials in hepatitis B (HBV) cure research: the ACTG A5394 study in persons with both HIV and HBV

Journal of Virus Eradication2023-08-243 citations

Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression.

2022-10-2935 citations